1. Home
  2. TYRA vs BW Comparison

TYRA vs BW Comparison

Compare TYRA & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$25.23

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$7.16

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
BW
Founded
2018
1867
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
TYRA
BW
Price
$25.23
$7.16
Analyst Decision
Strong Buy
Buy
Analyst Count
11
2
Target Price
$47.50
$8.00
AVG Volume (30 Days)
1.0M
4.2M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.46
EPS
N/A
N/A
Revenue
N/A
$1,062,388,000.00
Revenue This Year
N/A
$41.58
Revenue Next Year
N/A
$66.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.38
$2.64
52 Week High
$40.65
$22.03

Technical Indicators

Market Signals
Indicator
TYRA
BW
Relative Strength Index (RSI) 48.41 42.58
Support Level $24.58 $6.75
Resistance Level $27.02 $8.05
Average True Range (ATR) 2.07 0.46
MACD 0.15 0.10
Stochastic Oscillator 60.09 36.00

Price Performance

Historical Comparison
TYRA
BW

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.

Share on Social Networks: